vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and Primis Financial Corp. (FRST). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $45.6M, roughly 1.7× Primis Financial Corp.). Primis Financial Corp. runs the higher net margin — 16.0% vs -9.6%, a 25.6% gap on every dollar of revenue. Over the past eight quarters, Primis Financial Corp.'s revenue compounded faster (13.0% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Primis Financial Corp is a U.S.-based financial holding company operating full-service banking subsidiaries. It provides a comprehensive range of financial solutions including personal and commercial deposit products, diverse loan facilities, mortgage services, and wealth management support, primarily serving retail and corporate customers across the U.S. mid-Atlantic region.

BIOX vs FRST — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.7× larger
BIOX
$77.6M
$45.6M
FRST
Higher net margin
FRST
FRST
25.6% more per $
FRST
16.0%
-9.6%
BIOX
Faster 2-yr revenue CAGR
FRST
FRST
Annualised
FRST
13.0%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BIOX
BIOX
FRST
FRST
Revenue
$77.6M
$45.6M
Net Profit
$-7.4M
$7.3M
Gross Margin
46.8%
Operating Margin
9.3%
Net Margin
-9.6%
16.0%
Revenue YoY
-16.8%
Net Profit YoY
-20.2%
200.0%
EPS (diluted)
$-0.12
$0.30

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
FRST
FRST
Q1 26
$45.6M
Q4 25
$80.9M
Q3 25
$77.6M
$41.0M
Q2 25
$43.2M
Q1 25
$60.6M
$58.7M
Q4 24
$98.8M
$38.8M
Q3 24
$93.3M
$37.3M
Q2 24
$35.7M
Net Profit
BIOX
BIOX
FRST
FRST
Q1 26
$7.3M
Q4 25
$29.5M
Q3 25
$-7.4M
$6.8M
Q2 25
$2.4M
Q1 25
$-1.6M
$22.6M
Q4 24
$605.2K
$-26.2M
Q3 24
$-6.2M
$1.2M
Q2 24
$3.4M
Gross Margin
BIOX
BIOX
FRST
FRST
Q1 26
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Operating Margin
BIOX
BIOX
FRST
FRST
Q1 26
Q4 25
44.8%
Q3 25
9.3%
21.3%
Q2 25
6.9%
Q1 25
1.5%
41.9%
Q4 24
14.5%
-123.0%
Q3 24
2.5%
-3.1%
Q2 24
7.8%
Net Margin
BIOX
BIOX
FRST
FRST
Q1 26
16.0%
Q4 25
36.5%
Q3 25
-9.6%
16.7%
Q2 25
5.6%
Q1 25
-2.6%
38.6%
Q4 24
0.6%
-100.3%
Q3 24
-6.6%
3.3%
Q2 24
9.6%
EPS (diluted)
BIOX
BIOX
FRST
FRST
Q1 26
$0.30
Q4 25
$1.19
Q3 25
$-0.12
$0.28
Q2 25
$0.10
Q1 25
$-0.02
$0.92
Q4 24
$0.00
$-0.95
Q3 24
$-0.10
$0.05
Q2 24
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
FRST
FRST
Cash + ST InvestmentsLiquidity on hand
$15.5M
$159.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$427.2M
Total Assets
$734.9M
$4.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
FRST
FRST
Q1 26
$159.9M
Q4 25
$143.6M
Q3 25
$15.5M
$63.9M
Q2 25
$94.1M
Q1 25
$38.5M
$57.0M
Q4 24
$29.2M
$64.5M
Q3 24
$32.3M
$77.3M
Q2 24
$66.6M
Stockholders' Equity
BIOX
BIOX
FRST
FRST
Q1 26
$427.2M
Q4 25
$422.9M
Q3 25
$288.3M
$382.2M
Q2 25
$376.4M
Q1 25
$345.0M
$375.6M
Q4 24
$346.3M
$351.8M
Q3 24
$346.0M
$381.0M
Q2 24
$376.0M
Total Assets
BIOX
BIOX
FRST
FRST
Q1 26
$4.3B
Q4 25
$4.0B
Q3 25
$734.9M
$4.0B
Q2 25
$3.9B
Q1 25
$798.2M
$3.7B
Q4 24
$835.2M
$3.7B
Q3 24
$827.3M
$4.0B
Q2 24
$4.0B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
FRST
FRST
Operating Cash FlowLast quarter
$14.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
FRST
FRST
Q1 26
Q4 25
$10.8M
Q3 25
$14.4M
$-11.4M
Q2 25
$-41.0M
Q1 25
$23.3M
$34.4M
Q4 24
$-5.4M
$19.5M
Q3 24
$5.2M
$6.1M
Q2 24
$52.3M
Free Cash Flow
BIOX
BIOX
FRST
FRST
Q1 26
Q4 25
$9.0M
Q3 25
Q2 25
Q1 25
Q4 24
$18.3M
Q3 24
Q2 24
FCF Margin
BIOX
BIOX
FRST
FRST
Q1 26
Q4 25
11.2%
Q3 25
Q2 25
Q1 25
Q4 24
47.3%
Q3 24
Q2 24
Capex Intensity
BIOX
BIOX
FRST
FRST
Q1 26
Q4 25
2.1%
Q3 25
Q2 25
Q1 25
Q4 24
3.1%
Q3 24
0.0%
Q2 24
0.0%
Cash Conversion
BIOX
BIOX
FRST
FRST
Q1 26
Q4 25
0.36×
Q3 25
-1.67×
Q2 25
-16.82×
Q1 25
1.52×
Q4 24
-8.85×
Q3 24
4.93×
Q2 24
15.21×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIOX
BIOX

Segment breakdown not available.

FRST
FRST

Net Interest Income$32.1M70%
Noninterest Income$13.6M30%

Related Comparisons